The unique expression pattern of LAG‐3 in DLBCL shown by our analysis suggests that the combination of anti‐PD‐1/PD‐L1 and anti‐LAG‐3 inhibitors in the immunotherapy of DLBCL patients can have a synergistic effect and broaden the range of the TIMEs covered by immunotherapy, improving the immunotherapy efficacy and outcome in DLBCL patients. Here, PDCD1 is linked to diffuse large B-cell lymphoma.